# Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

> **NCT03816891** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 240 (actual)

## Conditions studied

- Prurigo Nodularis
- Pruritis

## Interventions

- **DRUG:** Vixarelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03816891
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-11
- **Primary completion:** 2022-12-28
- **Final completion:** 2023-08-24
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03816891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03816891, "Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03816891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*